---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-129738"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2021-10-26T23:59:59+00:00"
generated_at: "2026-06-28T17:55:14.508371+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyeGate closes Bayon acquisition, issues 33,798 shares; appoints Eric Daniels as CDO

## Summary
- Acquired Bayon Therapeutics for 33,798 common shares; up to $7.1M in milestone payments possible.
- Eric Daniels appointed CDO with base salary AUD$492,000 and option for 50,000 shares.
- CEO Brian Strem and new CDO Eric Daniels each owned ~28% of Bayon before acquisition.
- Milestone payments tied to clinical trial data and FDA approval of Bayon product candidates.

## SEC filing metadata
- accession: 0001104659-21-129738
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2021-10-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 5.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/0001104659-21-129738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/tm2130996d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-129738
- JSON: https://secwatch.observer/filing/0001104659-21-129738.json
- Plain text: https://secwatch.observer/filing/0001104659-21-129738.txt

## Key facts
- Executive change
  Eric J. Daniels was appointed as Chief Development Officer at KIORA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Chief Development Officer
  source text: the Board of Directors (the “Board”) of the Company appointed Eric J. Daniels, MD, MBA as Chief Development Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/0001104659-21-129738-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.